EP0777649A1 - N- 2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'antagonistes des recepteurs kappa - Google Patents

N- 2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'antagonistes des recepteurs kappa

Info

Publication number
EP0777649A1
EP0777649A1 EP95917437A EP95917437A EP0777649A1 EP 0777649 A1 EP0777649 A1 EP 0777649A1 EP 95917437 A EP95917437 A EP 95917437A EP 95917437 A EP95917437 A EP 95917437A EP 0777649 A1 EP0777649 A1 EP 0777649A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
compound
alkoxy
alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP95917437A
Other languages
German (de)
English (en)
Other versions
EP0777649B1 (fr
Inventor
Fumitaka Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0777649A1 publication Critical patent/EP0777649A1/fr
Application granted granted Critical
Publication of EP0777649B1 publication Critical patent/EP0777649B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel carboxamide compounds and their pharmaceutically acceptable salts, and to pharmaceutical compositions containing them. These compounds and compositions are useful as analgesic, antiinflammatory, diuretic or 0 neuroprotective agents for the treatment of a mammalian subject, especially a human subject.
  • analgesics such as mo ⁇ hine are therapeutically useful, but their usage is strictly limited because of their side effects such as drug dependency. Thus, analgesics 5 with high usefulness and reduced tendency to cause drug dependency are desired.
  • Considerable pharmacological and biochemical studies have been carried out to discover the opioid peptides and opioid receptors, and the discovery of the subtype of opioid receptor such as mu, delta, kappa at a peripheral nerve in a variety of species, including human, has made a beginning towards creating new analgesics.
  • opioid analgesics such as mo ⁇ hine act as a //-receptor agonist
  • separating the action based on a kappa-receptor agonist from the action based on ⁇ - receptor agonist has been investigated.
  • kappa-selective agonists have been reported from the above viewpoint for example, EMD-60400: A. Barber et al., Naunyn- Schmled. Arch. Pharmacol., 345 (Suppl.): Abst 456. Some of them actually have been 5 studied in clinical trials (Med. Res. Rev., 12, 525 (1992)).
  • the present invention provides a compound of the following formula:
  • Ar is phenyl or phenyl substituted with one to three substituents selected from halo, C,. * alkyl and C,. 4 alkoxy;
  • X is phenyl or heterocyclic; phenyl or heterocyclic substituted with one to three substituents selected from halo, C, ⁇ alkyl, C,.
  • R 2 and R 3 are each hydrogen, C, ⁇ alkyl, C, ⁇ alkoxy or C 7 .
  • phenylalkyl phenylalkyl
  • X 1 is phenyl, naphtyl, furyl, thienyl, pyridyl, thiazolyl, benzofuryl or benzothienyl
  • phenyl, naphtyl, furyl, thienyl, pyridyl, thiazolyl, benzofuryl or benzothienyl substituted with one to three substituents selected from halo, C, ⁇ alkyl, C, ⁇ alkoxy, amino, hydroxy, nitro, trifluoromethyl and mesyl.
  • the present invention provides a compound of the formula:
  • the carboxamide compounds of the present invention of formula (I) exhibit significant agonist activity toward opioid kappa receptor and are thus useful as analgesic, antiinflammatory, diuretic and neuroprotective agents, in mammals, especially man. Accordingly, the present invention also provides a pharmaceutical composition useful as an analgesic, antiinflammatory, diuretic or neuroprotective agent, in a mammal, especially man, which comprises atherapeutically effective amount of the carboxamide compound of formula (I) or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier.
  • heterocyclic means a monocyclic or bicyclic hydrocarbon group which has one or more hetero atoms in the ring, preferably has 4 to 10 carbon atoms and 1 to 3 heteroatoms, including piperidino, morpholino, thiamorpholino, pyrrolidino, pyrazolino, pyrazolidino, pyrazoryl, piperazinyl, furyl, benzofuryl, thienyl, benzothienyl, oxazolyl, tetrazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, pyrrolidinyl, quinolyl and quinuclidinyl.
  • a preferred group of compounds of this invention includes the compounds of formula (I) wherein R is hydroxy; Ar is phenyl optionally substituted with one to three halogen atoms, preferably phenyl; X is phenyl optionally substituted with one to three substituents selected from halo, C, ⁇ alkyl, C, ⁇ alkoxy and methoxycarbonyl; and X 1 is phenyl optionally substituted with one to three halogen atoms, preferably 3,4- dichlorophenyl.
  • Another preferred group of compounds of this invention includes the compounds of formula (I) wherein R is hydroxy; Ar is phenyl optionally substituted with one to three halogen atoms, more preferably phenyl; X is mono-, di- or tri-halomethyl, cyano, hydroxycarbonyl, butyloxycarbonyl, benzyloxycarbonyl, carbamoyl or hydroxymethyl; and X 1 is phenyl optionally substituted with one to three halogen atoms, preferably 3,4- dichlorophenyl.
  • Another preferred group of compounds of this invention includes the compounds of formula (I) wherein R is hydroxy; Ar is phenyl optionally substituted with one to three halogen atoms, more preferably phenyl; X is furyl, thienyl, pyridyl or oxadiazolyl; and X 1 is phenyl optionally substituted with one to three halogen atoms, preferably 3,4- dichlorophenyl.
  • Preferred individual compounds of the invention are: N-carboxymethyl-2-(3,4-dichlorophenyl)-N-[2-(3-(S)-hydroxypyrrolidin-1 -yl)-1 -(S)- phenylethyljacetamide; 2-(3,4-dichlorophenyl)-N-(2-hydroxyethyl)-N-[2-(3-(S)-hydroxypyrrolidin-1 -yl)-1 -(S)- phenylethyl]acetamide;
  • carboxaimde compounds of formula (I) of this invention may be prepared by a variety of synthetic methods.
  • the carboxamide compounds of formula (I) may be prepared by acylation of compound (II), as indicated in the following
  • the amine compound (II) is reacted with an acylating agent using standard acylating techniques known to those skilled in the art.
  • the amine compound (II) may be reacted with acyl halide (e.g., X 1 CH j COCI) in a suitable reaction-inert solvent.
  • Suitable inert-reaction solvents include, for example, aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as ethyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane; amides such as N,N- dimethylformamide; and nrtriles such as acetonitrile. If desired, this reaction may be catalyzed by a base such as triethylamine, pyridine or alkoxide.
  • aromatic hydrocarbons such as benzene, toluene and xylene
  • ethers such as ethyl ether, dioxane and tetrahydrofuran
  • halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane
  • amides such as N,N- dimethylformamide
  • the reaction may be carried out at a temperature of from -30°C to 100°C, preferably from 0°C to 25 °C, for 10 minutes to 48 hours, preferably from 30 minutes to 24 hours.
  • the compound (I) of the present invention may also be obtained from the amine compound (II) by the other acylation methods, for example, (1) a reaction with anhydride (e.g., (X 1 CH 2 CO) 2 O) or a mixed anhydride in the presence of base; (2) a reaction with carboxylic acid (X 1 CH 2 COOH) in the presence of a coupling agent such as dicyclohexylcarbodiimide (DCC), water soluble carbodiimide (WSCD), 2-ethoxy-N- ethoxycarbonyl-1 ,2-dihydroquinoline, Bop agent (Benzotriazol-1 -yloxy- tris(dimethylamino)phosphonium hexafluorophosphate), diethyl azodicarboxylate-
  • the compound (I) of the present invention may be prepared by the following Preparation Method A-ll.
  • Preparation Method A-ll Preparation Method A-ll:
  • the compound (I) may be obtained by alkylation of the amide compound (III). Alkylation methods known to those skilled in the art can be used.
  • the amide compound (III) may be reacted with alkylhalide (e.g., XCH 2 L wherein X is as previously defined; and L is halo such as chloro) in a reaction-inert solvent.
  • alkylhalide e.g., XCH 2 L wherein X is as previously defined; and L is halo such as chloro
  • this reaction may be catalyzed by a base such as sodium, sodium hydride, sodium hydroxide, potassium hydroxide, with or without a phase-transfer catalyst.
  • the reaction may be carried out at a temperature of from 0°C to 200°C, preferably from 60°C to 150°C, for 5 minutes to 24 hours, preferably from 30 minutes to 12 hours.
  • the alkylation of the compound (III) may be carried out by reacting the compound (III) with formaldehyde and metal salts (e.g., MX wherein X is as previously defined; and M is an alkali metal such as sodium and potassium) in a suitable reaction- inert solvent.
  • the amide compound (III) may be obtained by acylation of the amine compound (IV) in similar procedures to those described in Preparation Method A-l above.
  • the amine compound (II) may be obtained by the following Preparation Method B-l.
  • Preparation Method B-l Preparation Method B-l:
  • the amine compound (II) may be obtained by alkylation of the amine compound (IV) using standard alkylation techniques known to those skilled in the art.
  • a preferred alkylation method is reductive alkylation wherein the amine compound (IV) may be reacted with aldehyde, XCHO (wherein X is as already defined) in the presence of a reducing agent such as NaBH 4 , NaBH 3 CN or NaBH(OAc) 3 .
  • This reaction may be carried out in a suitable reaction-inert solvent at a temperature of from -20°C to 60°C, preferably from 0°C to 25°C, for 10 minutes to 48 hours, preferably from 60 minutes to
  • the amine compound (II) may be obtained by reacting the amine compound (IV) with alkylhalide, XCH 2 L (wherein X and L are as already defined) under conditions known to those skilled in the art.
  • the Mannich type alkylation can be also used, which comprises the reaction of the compound (IV) with formaldehyde and a metal salt.
  • the amine compounds (IV) are either known or may be prepared by known methods as described in European Patent No. 254545.
  • the amine compound (II) may be obtained by acylation of the compound
  • the amine compound (IV) may be first reacted with acylating agents, XCOOH (wherein X is as already defined) in the presence of a suitable coupling agent as mentioned above, in a suitable reaction-inert solvent, followed by reduction using a reducing agent such as LiAIH 4 , BH 3 -Me 2 S or BH 3 -THF.
  • a suitable coupling agent such as LiAIH 4 , BH 3 -Me 2 S or BH 3 -THF.
  • This reaction may be carried out at a temperature of from 0°C to 100°C, preferably from 20 C C to 80°C, for 30 minutes to 24 hours, preferably from 60 minutes to 12 hours.
  • the other possible acylation methods prior to the reduction include a reaction of the compound (IV) with acyl halide, XCOL in the presence of base; and the reaction of the compound (IV) with anhydride, (XCO) 2 O in the presence of base.
  • the conditions to be employed for these acylation methods can be appropriately chosen by those skilled in the art.
  • the compound (II) may be obtained by acylation of an amide compound of the following formula (V), followed by reduction, as indicated in the following Preparation Method B-lll.
  • Preparation Method B-lll Preparation Method B-lll:
  • the amide compound (V) may be first subjected to acylation as mentioned in the above Preparation Method B-ll, and then subjected to reduction, to obtain the compound (II).
  • the conditions for this reaction may be similar to those described in the above Preparation Method B-ll.
  • the amide compound (V) is either known or can be prepared by known methods as described in, for example, European Patent No. 254545 and Chem. Pharm. Bull., 42(3) 690-693, 1994.
  • the compounds of formula (I), and the intermediates shown in the above Preparation Methods can be isolated and purified by conventional procedures, such as recrystallisation or chromatographic purification.
  • carboxamide compounds of this invention possess at least two asymmetric centers, they are capable of occurring in various stereoisomeric forms or configurations. Hence, the compounds can exist in separated (+)• and (-)-optically active forms, as well as mixtures thereof.
  • the present invention includes all such forms within its scope. Individual isomers can be obtained by known methods, such as optically selective reaction or chromatographic separation in the preparation of the final product or its intermediate.
  • the carboxamide compounds of the present invention can be used in the form of the inorganic salts with acid such as hydrochloric acid, hydrobromic acid, sulfonic acid, nitric acid, phosphoric acid and the like and the organic salts with acid such as acetic acid, formic acid, benzoic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, citric acid, alkylsulfonic acid.
  • acid such as hydrochloric acid, hydrobromic acid, sulfonic acid, nitric acid, phosphoric acid and the like
  • organic salts with acid such as acetic acid, formic acid, benzoic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, citric acid, alkylsulfonic acid.
  • the carboxamide compounds of the present invention of formula (I) exhibit significant agonist activity toward opioid kappa receptor and are thus useful as analgesic, antiinflammatory, diuretic and neuroprotective agents for the treatment of mammals, especially humans in need of such agents.
  • the activity of the carboxamide compounds of formula (I) of the present invention as opioid kappa agonist is demonstrated by the opioid receptor binding activity.
  • Such activity may be determined in homogenates from guinea pig whole brain, as described by Regina, A. et al. in J. Receptor Res. 12: 171-180, 1992. In summary, tissue homogenate is incubated at 25 °C for 30 min in the presence of labelled ligand and test compounds.
  • the /x-sites are labelled by 1 nM of (3H)-[D-Ala2,MePhe4,Gly-ol5]enkephalin (DAMGO), the ⁇ -sites by 1 nM of (3H)-[D-Pen2,5]enkephalin (DPDPE) and the ⁇ -sites by 0.5 nM (3H)-CI-977.
  • the non specific binding is measured by use of 1 mM CI-977 (K), 1 mM (DAMGO) ( t), lmM (DPDPE) ( ⁇ ).
  • Data are expressed as the IC*, values obtained by a non ⁇ linear fitting program using the Cheng and Prusoff equation. All compounds prepared in the Working Examples as described below were tested by this method, and showed an IC*, value of 0.01 nM to lO ⁇ M with respect to inhibition of binding at its receptor.
  • the agonist activity toward opioid kappa receptor can also be demonstrated by the Formalin Test as described by Wheeler-Aceto, H. et al. in Psychopharmacology 104: 35-44, 1991.
  • male SD rats (80-100 g) are injected s.c. with a test compound dissolved in 0.1% methyl cellulose saline or vehicle.
  • 50 ml of a 2% formalin are injected into a hind paw.
  • the number of licking the injected paw per observation period is measured 15-30 min. after the injection of formalin and expressed as % inhibition compared to the respective vehicle group.
  • the agonist activity toward opioid kappa receptor can also be demonstrated by the Rotarod Test as described by Hayes, A.G. et al. in Br. J. Pharmacol. 79: 731-736, 1983.
  • a group of 6-10 male SD rats (100-120 g) are selected for their ability to balance on a rotating rod (diameter 9 cm, rate of rotation 5 r.p.m.).
  • the selected rats are then injected s.c. with a test compound dissolved in 0.1% methyl cellulose saline.
  • the animals are tested again 30 min. after treatment; a rat falling off the bar more than twice within 150 seconds is considered to be showing motor impairment and the animal's performance (i.e., time on the rotarod) are recorded.
  • the Rotarod Test as described by Hayes, A.G. et al. in Br. J. Pharmacol. 79: 731-736, 1983.
  • the selected rats are then injected s.c. with a test
  • ED jo value defined as the dose of the drug which halves the performance time is obseraved in the control group.
  • the carboxamide compounds of formula (I) of this invention can be administered via either the oral, parenteral or topical routes to mammals.
  • these compounds are most desirably administered to humans in doses ranging from 0.01 mg to 100 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated, the disease state being treated and the particular route of administration chosen.
  • a dosage level that is in the range of from 0.01 mg to 50 mg per kg of body weight per day is most desirably employed for the treatment of pain in a postoperative patient.
  • the compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the above routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents, etc.
  • oralpharmaceutical compositions can be suitably sweetened and/or flavored.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging 5% to 70% by weight, preferably 10% to 50% by weight.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dipotassium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type may also be employed as fillers in gelatine capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene grycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • the aqueous solutions should be suitably buffered (preferably pH > 8) if necessary and the liquid diluent first rendered isotonic.
  • These aqueous solutions are suitable for intravenous injection purposes.
  • the oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
  • IR(neat) 3400, 1740, 1650cm 1 .
  • This compound was prepared in 48% yield according to a procedure similar to diat described in Example 1.
  • HCI salt amo ⁇ hous solid.
  • Example 8 2-f .4-Dichlorophenvn-N-, f 2-( 3-fS Vhvdroxypyrrolidin- 1 -ylV 1 -(S Vphenylethvn-N-(2.2.2- trifluoroefliyDacetamide This compound was prepared in 38.9% yield according to a procedure similar to tiiat described in Example 1.
  • This compound was prepared in 96.5% yield according to a procedure similar to tiiat described in Example 1.
  • Example 12 2-(3.4-Dichlorophenvn-N-r2-(3-fSVhvdroxypyrrolidin-l-vn-l-fSVphenylethyll-N-r2- tiiienyPmethylacetamide This compound was prepared in 62.6% yield according to a procedure similar to that described in Example 1.
  • This compound was prepared in 63.9% yield according to a procedure similar to tiiat described in Example 9.
  • Example 14 2-( .4-DichlorophenylVN-r2-('3-f SVhvdroxyDyrrolidin- 1 -ylV 1 -(S Vphenylethyll-N-f 3- pyridv ⁇ mediylacetamide This compound was prepared in 56.7% yield according to a procedure similar to that described in Example 1.
  • Example 15 f2S.3SVl-r2-Phenyled ⁇ yl-2-N- ⁇ ' 2-pyridyl')med ⁇ ylaminol-3-hvdroxypyrrolidine This compound was prepared in 37.9% yield according to a procedure similar to that described in Example 9.
  • This compound was prepared in 78.5% yield according to a procedure similar to that described in Example 1.
  • This compound was prepared in 46.6% yield according to a procedure similar to tiiat described in Example 1.
  • reaction mixture was diluted witii CH 2 C1 2 (20ml), washed with saturated NaHC0 3 aqueous solution and brine, dried (Na 2 S0 4 ), and concentrated to give 1.05g of brown viscous oil.
  • Example 24 2-f3.4-Dichlorophenvn-N-(2.2-difluoroethvn-N-r2-(3-fSVhvdroxyDyrrolidin-l-vn-l-(SV phenylethyllacetamide This compound was prepared in 62.7% yield according to a procedure similar to that described in Example 1.
  • HCI salt amo ⁇ hous solid Anal. Calcd for : C, 51.63 ; H, 5.32 ; N, 5.47. Found : C, 51.94 ; H, 5.40 ; N, 5.51.
  • the reaction mixture was diluted with water (10ml) , basified widi IN NaOH aqueous solution to pH12, and extracted with CH 2 C1 2 (30ml x 3). The extract was dried (Na ⁇ OJ and concentrated in vacuo to give l.OOg of dark brown viscous oil, which was purified by column chromatography (silica gel: lOOg, CH 2 Cl 2 /MeOH : 30/1 as eluent) to afford 0.51g (43%) of brown viscous oil.
  • Example 26 (2S .3S)- 1 -(2-N-Benzylamino-2-phe ⁇ ylethyl)-3-hydroxypyrrolidine This compound was prepared in 100% yield according to a procedure similar to tiiat described in Example 9.
  • Example 27 N-Benzvl-2-r3.4-DichloroDhenvn-N-r2-f3-(S hvdro ⁇ ypyrrolidin-l-vn-1-rS phe ⁇ vlethvnacetamide This compound was prepared in 62.6% yield according to a procedure similar to that described in Example 1.
  • N-r2-methoxvethvnacetamide This compound was prepared in 77.2% yield according to a procedure similar to tiiat described in Example 1.
  • HCI salt amo ⁇ hous solid.
  • This compound was prepared in 64.8% yield according to a procedure similar totiiat described in Example 1.
  • HCI salt amo ⁇ hous solid.
  • Example 36 2-G.4-DichloroDhenvn-N-('2.2-dimethoxyethvn-N-r2-f3-( , S')-hvdroxynyrrolidin-l-vn-l-fSV phenvlethvllacetamide This compound was prepared in 91.2% yield according to a procedure similar to tiiat described in Example 1.
  • Fumalic acid salt amo ⁇ hous solid.
  • This compound was prepared in 100% yield according to a procedure similar to tiiat described in Example 9.
  • Fumalic acid salt amo ⁇ hous solid.
  • This compound was prepared in 100% yield according to a procedure similar to that described in Example 9.
  • Fumalic acid salt amo ⁇ hous solid.
  • Anal. Calcd for C ⁇ H-F,N 3 O 4 -C 4 H 4 O 4 -0.5H 2 O C, 57.04; H, 5.47; N, 4.75.
  • Fumalic acid salt mp 78-80.5 * .
  • Fumalic acid salt amo ⁇ hous solid.
  • Fumalic acid salt amo ⁇ hous solid.
  • Fumalic acid salt amo ⁇ hous solid.
  • Example 54 ( ' 2S.3SVl-f2-N-(T ⁇ N'-DimethylaminocarbonvPme-iylamino-2-phenyleti ⁇ y ⁇ -3-hvdroxypyrrolidine
  • (2S,3S)-l-(2-arnino-2-phenylethyl)-3-hydroxypyrrolidine (0.413g, 2mmol), 2- chloro-N,N-dimethylacetamide (292mg, 2.4mmol), and (276mg, 2mmol) in DMF (4ml) was stirred at 50' for 2.5h.
  • the reaction mixture was poured into water(l ⁇ ml) and extracted witii ethyl acetate(20ml x 3).
  • Fumalic acid salt amo ⁇ hous.
  • HCI salt amo ⁇ hous solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP95917437A 1994-08-24 1995-05-18 N- 2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'agonistes des recepteurs kappa Expired - Lifetime EP0777649B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/JP94/01399 1994-08-24
PCT/JP1994/001399 WO1996006078A1 (fr) 1994-08-24 1994-08-24 N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides utilises en tant qu'antagonistes du recepteur kappa
PCT/IB1995/000374 WO1996006077A1 (fr) 1994-08-24 1995-05-18 N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'antagonistes des recepteurs kappa

Publications (2)

Publication Number Publication Date
EP0777649A1 true EP0777649A1 (fr) 1997-06-11
EP0777649B1 EP0777649B1 (fr) 1999-07-14

Family

ID=14098616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95917437A Expired - Lifetime EP0777649B1 (fr) 1994-08-24 1995-05-18 N- 2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'agonistes des recepteurs kappa

Country Status (17)

Country Link
US (1) US5837720A (fr)
EP (1) EP0777649B1 (fr)
JP (1) JP2935899B2 (fr)
AT (1) ATE182138T1 (fr)
AU (1) AU2350695A (fr)
BR (1) BR9503775A (fr)
CA (1) CA2196885C (fr)
CO (1) CO4410322A1 (fr)
DE (1) DE69510802T2 (fr)
DK (1) DK0777649T3 (fr)
ES (1) ES2133767T3 (fr)
FI (1) FI116056B (fr)
GR (1) GR3031133T3 (fr)
IL (1) IL114969A0 (fr)
MX (1) MX9701367A (fr)
TR (1) TR199501055A2 (fr)
WO (2) WO1996006078A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
WO1998049141A1 (fr) * 1997-04-30 1998-11-05 Warner-Lambert Company Agonistes d'opioïdes kappa
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
CA2288828A1 (fr) * 1997-07-14 1999-01-28 Adolor Corporation Compositions pharmaceutiques anti-pruritiques contenant des agonistes de recepteurs kappa et procede de traitement du prurit a l'aide desdites compositions
US6284769B1 (en) 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
CA2907921C (fr) * 2013-03-22 2021-09-07 Ayumi Pharmaceutical Corporation Inhibition de la production d'il-2
WO2014210436A2 (fr) * 2013-06-28 2014-12-31 Nektar Therapeutics Agonistes opioïdes kappa et leurs utilisations
EP3097093A1 (fr) * 2014-01-24 2016-11-30 Cadila Healthcare Limited Nouveaux composés hétérocycliques utilisés comme agonistes opioïdes kappa
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
WO2018195439A2 (fr) 2017-04-20 2018-10-25 The Regents Of The University Of California Modulateurs de k-ras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9606077A1 *

Also Published As

Publication number Publication date
DE69510802D1 (de) 1999-08-19
ATE182138T1 (de) 1999-07-15
JPH09510731A (ja) 1997-10-28
GR3031133T3 (en) 1999-12-31
US5837720A (en) 1998-11-17
WO1996006077A1 (fr) 1996-02-29
FI116056B (fi) 2005-09-15
FI970746A (fi) 1997-02-21
CA2196885A1 (fr) 1996-02-29
DK0777649T3 (da) 1999-11-29
MX9701367A (es) 1997-05-31
ES2133767T3 (es) 1999-09-16
CA2196885C (fr) 2001-01-23
FI970746A0 (fi) 1997-02-21
DE69510802T2 (de) 1999-11-04
BR9503775A (pt) 1996-04-16
EP0777649B1 (fr) 1999-07-14
AU2350695A (en) 1996-03-14
CO4410322A1 (es) 1997-01-09
IL114969A0 (en) 1995-12-08
WO1996006078A1 (fr) 1996-02-29
JP2935899B2 (ja) 1999-08-16
TR199501055A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
EP0777649B1 (fr) N- 2-(pyrrolidinyl-1)-1-phenylethyl]acetamides utilises en tant qu'agonistes des recepteurs kappa
WO2010094678A1 (fr) Nouveaux ortho-aminoamides pour le traitement du cancer
EP0817772B1 (fr) Composes d'acide pyrrolidinyl-hydroxamique et leur procede de production
US6313302B2 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
JP2849128B2 (ja) 炭化水素置換ピロリジノン類
CA2069423A1 (fr) Derives azacycliques
Galeazzi et al. Thermodynamic vs. kinetic control in the stereoselective intramolecular conjugate addition of amide enolates leading to chiral trans-3, 4-disubstituted pyrrolidin-2-ones
EP0789021B1 (fr) Dérivés d'acide hydroxamique et leur utilisation comme agonistes du récepteur opioid kappa
MXPA97007454A (en) Hydroxamic pirrolidinil acid compounds and their product procedure
CZ92199A3 (cs) Pyrrolidinyl- a pyrrolinylethylaminové sloučeniny, způsob a meziprodukty pro jejich výrobu, farmaceutická kompozice na jejich bázi a způsob léčení chorob

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19971128

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 182138

Country of ref document: AT

Date of ref document: 19990715

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REF Corresponds to:

Ref document number: 69510802

Country of ref document: DE

Date of ref document: 19990819

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2133767

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19990907

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050406

Year of fee payment: 11

Ref country code: AT

Payment date: 20050406

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050407

Year of fee payment: 11

Ref country code: DK

Payment date: 20050407

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20050411

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20050414

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20050421

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050503

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050517

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050520

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050527

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050531

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050603

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050613

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060518

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060518

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060519

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060531

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061201

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060518

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20061120

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20061201

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070131

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060519

BERE Be: lapsed

Owner name: *PFIZER INC.

Effective date: 20060531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070518